Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Cite this paper

@article{Topp2012LongtermFO, title={Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.}, author={Max S. Topp and Nicola Goekbuget and Gerhard Zugmaier and Evelyn Degenhard and M Goebeler and Matthias Klinger and Svenja A Neumann and Heinz August Horst and Thorsten Raff and Andreas a Viardot and Matthias Stelljes and Markus Schaich and Rudolf Koehne-Volland and Monika Br{\"{u}ggemann and Oliver G Ottmann and Thomas Burmeister and Patrick A. Baeuerle and Dirk Nagorsen and Margit Schmidt and Hermann Einsele and Gert Riethmueller and Michael Kneba and Dieter Hoelzer and Peter Kufer and Ralf Christian Bargou}, journal={Blood}, year={2012}, volume={120 26}, pages={5185-7} }